Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells

Oncogene

Volumn 26, Issue 2, 2007, Pages 248-257

  Vogler, M ^a   Durr K ^a   Jovanovic, M ^a   Debatin, K M ^a   Fulda, S ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Pancreatic cancer; Resistance; TRAIL; XIAP

Indexed keywords

CASPASE; CYTOCHROME C; FAS ANTIGEN; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL DEATH; CELL MEMBRANE POTENTIAL; CELL SURVIVAL; CLONOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; RNA INTERFERENCE; TREATMENT RESPONSE;

APOPTOSIS; CASPASES, EFFECTOR; CYTOCHROMES C; HUMANS; LIGANDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; PANCREATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RETROVIRIDAE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 33846222280     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209776     Document Type: Article

References (38)

1. Ashkenazi A. (2002). Nat Rev Cancer 2: 420-430.
2. Amantana A, London CA, Iversen PL, Devi GR. (2004). Mol Cancer Ther 3: 699-707.
3. Bardeesy N, DePinho RA. (2002). Nat Rev Cancer 2: 897-909.
4. Bilim V, Kasahara T, Hara N, Takahashi K, Tomita Y. (2003). Int J Cancer 103: 29-37.
5. Brummelkamp TR, Bernards R, Agami R. (2002). Science 296: 550-553.
6. Burstein E, Ganesh L, Dick RD, van De Sluis B, Wilkinson JC, Klomp LW et al. (2004). EMBO J 23: 244-254.
7. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. (2004). Cell Death Differ 11: 915-923.
8. Cory S, Adams JM. (2002). Nat Rev Cancer 2: 647-656.
9. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. (2004). Cancer Res 64: 3006-3008.
10. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. (2003). Oncogene 22: 3842-3852.
11. Fulda S, Debatin KM. (2004a). Vitam Horm 67: 275-290.
12. Fulda S, Debatin KM. (2004b). Curr Cancer Drug Targets 4: 569-576.
13. Fulda S, Meyer E, Debatin KM. (2002a). Oncogene 21: 2283-2294.
14. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. (1997). Cancer Res 57: 3823-3829.
15. Fulda S, Wick W, Weller M, Debatin KM. (2002b). Nat Med 8: 808-815.
16. Gerhard MC, Schmid RM, Hacker G. (2002). Br J Cancer 86: 893-898.
17. Hao Y, Sekine K, Kawabata A, Nakamura H, Ishioka T, Ohata H et al. (2004). Nat Cell Biol 6: 849-860.
18. Hengartner MO. (2000). Nature 407: 770-776.
19. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E et al. (2000). Oncogene 19: 5477-5486.
20. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP et al. (2003). Clin Cancer Res 9: 2826-2836.
21. Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D et al. (2001). Pancreas 23: 72-79.
22. LeBlanc HN, Ashkenazi A. (2003). Cell Death Differ 10: 66-75.
23. Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH. (2004). Cancer Gene Ther 11: 309-316.
24. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S et al. (2004). Oncogene 23: 8105-8117.
25. Mohr A, Zwacka RM, Debatin KM, Stahnke K. (2004). Cell Death Differ 11: 1153-1154.
26. Parker SL, Tong T, Bolden S, Wingo PA. (1997). CA Cancer J Clin 47: 5-27.
27. Saelens X, Festjens N, Walle LV, van Gurp M, van Loo G, Vandenabeele P. (2004). Oncogene 23: 2861-2874.
28. Salvesen GS, Duckett CS. (2002). Nat Rev Mol Cell Biol 3: 401-410.
29. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. (2000). Cancer Res 60: 5659-5666.
30. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. (2001). Pancreas 23: 251-258.
31. Schneider G, Siveke JT, Eckel F, Schmid RM. (2005). Gastroenterology 128: 1606-1625.
32. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W et al. (1989). Science 245: 301-305.
33. Trauzold A, Schmiedel S, Roder C, Tams C, Christgen M, Oestern S et al. (2003). Br J Cancer 89: 1714-1721.
34. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S et al. (2001). Oncogene 20: 4258-4269.
35. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. (2006). Hum Pathol 37: 78-86.
36. Westphal S, Kalthoff H. (2003). Mol Cancer 2: 6.
37. Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA et al. (2000). Invest New Drugs 18: 43-56.
38. Yang L, Cao Z, Yan H, Wood WC. (2003). Cancer Res 63: 6815-6824.